PIPELINE
台康生技開發高質量的生物產品，推進廣泛的候選產品線，以改善患者的生活。
| 產品名稱 | 藥物類別 | 適應症 | 標靶/靶點 | 研發進度 | 合作夥伴 | |||
|---|---|---|---|---|---|---|---|---|
| 臨床前試驗 | 臨床一期 | 臨床二/三期 | 上市許可申請 | |||||
EG12014 (EIRGASUN®/HERWENDA®) Trastuzumab Biosimilar | Monoclonal Antibody | Breast Cancer | HER 2 |  |  | |||
EG1206A Pertuzumab Biosimilar | Monoclonal Antibody | Breast Cancer | HER 2 | |  | |||
EG12043 (TSY0110) Ado-trastuzumab emtansine Biosimilar | Antibody Drug Conjugate (ADC) | Breast Cancer | HER 2 | |  | |||
EG13074 TRZ (SC formulation) | Monoclonal Antibody | Breast Cancer | HER 2 | | - | |||
EG13084 TRZ + PTZ (SC formulation) | Monoclonal Antibody | Breast Cancer | HER 2 | | - | |||
EG1211X IO | Monoclonal Antibody | Breast Cancer | PD-L1 | | - | |||
EG1216X Hemato-oncology | Monoclonal Antibody | Breast Cancer | CD38 | | - | |||
EG12014 (EIRGASUN@/HERWENDA@) Trastuzmab Biosimilar
Contract Development
台康生技成立於2012年，專注於生物藥品的開發與CDMO委託製造服務，擁有兩座符合國際標準的cGMP廠房，服務涵蓋細胞株開發至量產製程。目前正積極開發包含乳癌與眼疾治療在內的多項生物藥與疫苗載體蛋白。
EG1206A Pertuzumab Biosimilar
Achieving Mutual Growth
台康生技成立於2012年，專注於生物藥品的開發與CDMO委託製造服務，擁有兩座符合國際標準的cGMP廠房，服務涵蓋細胞株開發至量產製程。目前正積極開發包含乳癌與眼疾治療在內的多項生物藥與疫苗載體蛋白。
EG1206A Pertuzumab Biosimilar
Contract Development
In March 2013, EirGenix undertook the two cGMP pilot plants—one for mammalian cell and one for microbial—as well as the outstanding DCB technicians. With the predecessors’ accumulated experiences as the starting point, EirGenix managed to quickly gain a steady foothold.
EG1206A Pertuzumab Biosimilar
4
